Bangladesh, Sept. 30 -- IBN Sina Pharmaceuticals registered a 25.4 per cent growth in profit to Tk 794 million in FY26, supported by higher sales and improved operational efficiency.

The drug maker reported consolidated earnings per share (EPS) of Tk 25.43 for the year, up from Tk 20.27 in the previous year.

Its standalone profit also increased 12 per cent year-on-year to Tk 740 million in FY26.

Following the higher profit, the company's board recommended a 77 per cent cash dividend for FY26, its highest payout in recent years, compared with a 64 per cent cash dividend paid for FY25.

Shareholders will receive Tk 7.70 in cash dividend for each share against earnings of Tk 25.43 per share, implying a payout ratio of around 30 per cent....